outperform price
chang price earn report
consist execut win day
debat morn post print
quit robust convers call seem
calm pre market jitter bear pounc peak
revenu peak margin hypothesi whether could
achiev organ event libr get
approv bull take comfort fact abt
execut superl key product
mitraclip alin continu remain track libr
slippag pushback take step back see
sustain high singl digit top-line continu
believ libr approv doubl digit ep
medium term think kind topline/ earn visibl
rare larg cap land stage cycl
increas macro concern see abt growth larg
insul macro bar fx tricki
real risk thesi medicare-for-al
scenario think remain low probabl event
given visibl tweak pt
price-to-earnings rais number slightli
libr momentum remain track came estimate
guid impli strong margin uplift leverag
lesser fx hw well
approv timelin libr misjudg
open item w/ fda work
neuromod littl softer vs st due sale forc ramp
go slower expect
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
organ sale growth high end rang
ep rang narrow worsen fx
organ sale growth
fx impact somewhat bp
organ growth signific add user base
expand reimburs ontario quebec
look expand cross-us w/ omada sanofi tandem
confid canada ramp previous seen geographi
work open item w/ fda comment timelin
begin ramp alin us clinic hurdl clear
legaci architect system us still outperform market
mitraclip grew in-lin management expect growth overal driven growth
us
nutrit busi seem ignor econom issu
demand product still strong challeng pediatr nutrit lower birth rate
focu execut
non-oper item impact royalti relat st jude etc
stent gain share us
dd endo peripher busi
ahead leverag target
 radar screen bolt-ons/tuck-in primarili
invest manufactur expans
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin octob
analyst jon bristow vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
